Many businesses are empty, so yield management will be big.

FORBES: Live: Groupon's Andrew Mason Won't Talk About Google Rumors

Four big pharma were not so lucky: Abbott, Amgen, AstraZeneca, and Lilly ended the year empty-handed.

FORBES: The FDA approvals of 2012: are we making progress?